Inhibition of apoptosis signal–regulating kinase 1, a serine/threonine kinase, leads to
improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis. We …

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease
that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown …

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of NAFLD …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population,
and has no approved drug therapy. Although pharmacotherapies are in development, …

In the past decade, an exciting realization has been that diverse liver diseases — ranging
from nonalcoholic steatohepatitis, alcoholic steatohepatitis and cirrhosis to hepatocellular …

Dysregulation of the gut microbiome has been implicated in the progression of non-alcoholic
fatty liver disease (NAFLD) to advanced fibrosis and cirrhosis. To determine the diagnostic …

One quarter of the global population is estimated to have nonalcoholic fatty liver disease (NAFLD).
The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by up …

Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a
potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal …

AASLD Practice Guidance on the clinical assessment and manag... : Hepatology AASLD
Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver …